Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Olivier, Christoph B."" wg kryterium: Autor


Tytuł :
Triple antithrombotic therapy in cardiac patients: more questions than answers.
Autorzy :
Moser M; Heart Center, Cardiology and Angiology I, Freiburg University, Hugstetter Strasse 55, Freiburg 79106, Germany.
Olivier CB
Bode C
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2014 Jan; Vol. 35 (4), pp. 216-23. Date of Electronic Publication: 2013 Dec 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Cardiovascular Diseases/*drug therapy
Fibrinolytic Agents/*therapeutic use
Administration, Oral ; Anticoagulants/administration & dosage ; Drug Administration Schedule ; Drug Therapy, Combination ; Drug-Eluting Stents ; Embolism/prevention & control ; Graft Occlusion, Vascular/prevention & control ; Hemorrhage/prevention & control ; Humans ; Percutaneous Coronary Intervention ; Practice Guidelines as Topic ; Precision Medicine ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Randomized Controlled Trials as Topic ; Stroke/prevention & control ; Vitamin K/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany, christoph.olivier@universitaets-herzzentrum.de.
Schnabel K
Brandt C
Weik P
Olschewski M
Zhou Q
Bode C
Diehl P
Moser M
Pokaż więcej
Źródło :
Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2014 Dec; Vol. 103 (12), pp. 968-75. Date of Electronic Publication: 2014 Jul 16.
Typ publikacji :
Journal Article; Observational Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Myocardial Revascularization*
Stents*
Adenosine Diphosphate/*blood
Coronary Artery Disease/*surgery
Peptide Fragments/*blood
Platelet Aggregation/*physiology
Postoperative Complications/*mortality
Aged ; Coronary Artery Disease/blood ; Coronary Artery Disease/mortality ; Female ; Follow-Up Studies ; Germany/epidemiology ; Humans ; Male ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Function Tests ; Prospective Studies ; Receptors, Cell Surface ; Survival Rate/trends ; Ticlopidine/therapeutic use
Czasopismo naukowe
Tytuł :
TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Autorzy :
Olivier CB; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany. Electronic address: Christoph.Olivier@universitaets-herzzentrum.de.
Weik P; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Meyer M; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany.
Anto-Michel N; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Diehl P; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Zhou Q; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Geisen U; Medical Center-University of Freiburg, Institute for Clinical Chemistry and Laboratory Medicine, Freiburg, Germany.
Bode C; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Moser M; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2016 Feb; Vol. 138, pp. 63-68. Date of Electronic Publication: 2015 Nov 01.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antithrombins/*therapeutic use
Atrial Fibrillation/*drug therapy
Blood Platelets/*drug effects
Dabigatran/*therapeutic use
Platelet Aggregation/*drug effects
Receptors, Thrombin/*metabolism
Rivaroxaban/*therapeutic use
Aged ; Aged, 80 and over ; Antithrombins/pharmacology ; Dabigatran/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Pulmonary Embolism/drug therapy ; Rivaroxaban/pharmacology ; Venous Thrombosis/drug therapy
Czasopismo naukowe
Tytuł :
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Schnabel K; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University Freiburg, Freiburg, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Jul; Vol. 42 (1), pp. 84-9.
Typ publikacji :
Journal Article
MeSH Terms :
Body Weight*
Platelet Activation/*drug effects
Purinergic P2Y Receptor Antagonists/*administration & dosage
Adenosine/administration & dosage ; Adenosine/analogs & derivatives ; Clopidogrel ; Dose-Response Relationship, Drug ; Drug Dosage Calculations ; Humans ; Platelet Aggregation/drug effects ; Prasugrel Hydrochloride/administration & dosage ; Purinergic P2Y Receptor Antagonists/pharmacology ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Ticagrelor ; Ticlopidine/administration & dosage ; Ticlopidine/analogs & derivatives
Czasopismo naukowe
Tytuł :
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Weik P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Meyer M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Aug; Vol. 42 (2), pp. 161-6.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Dabigatran/*pharmacology
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*therapeutic use
Rivaroxaban/*pharmacology
Adenosine Diphosphate/metabolism ; Antithrombins/pharmacology ; Antithrombins/therapeutic use ; Arachidonic Acid/metabolism ; Clopidogrel ; Dabigatran/therapeutic use ; Drug Therapy, Combination ; Humans ; Rivaroxaban/therapeutic use ; Ticlopidine/analogs & derivatives
Czasopismo naukowe
Tytuł :
MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation.
Autorzy :
Zhou Q; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Einert M; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Schmitt H; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Wang Z; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Pankratz F; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Bode C; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Liao JK; Section of Cardiology, University of Chicago Medical Center, Chicago, IL, USA. Electronic address: .
Moser M; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany. Electronic address: .
Pokaż więcej
Źródło :
Vascular pharmacology [Vascul Pharmacol] 2016 Sep; Vol. 84, pp. 67-73. Date of Electronic Publication: 2016 Jul 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents/*pharmacology
Inflammation/*drug therapy
Metalloporphyrins/*pharmacology
Vascular Diseases/*pathology
Animals ; Bone Morphogenetic Protein Receptors, Type II/genetics ; Cell Adhesion ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Human Umbilical Vein Endothelial Cells ; Inflammation/pathology ; Leukocytes/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Signal Transduction/drug effects ; Smad Proteins/metabolism ; Superoxide Dismutase/metabolism ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.
Autorzy :
Rilinger J; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Meyer M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Schnabel K; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Weik P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Charlet A; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Esser JS; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Nov; Vol. 42 (4), pp. 558-65.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Observational Study
MeSH Terms :
Atrial Fibrillation*/blood
Atrial Fibrillation*/therapy
Receptors, Purinergic P2Y12*
Stents*
Thromboembolism*/blood
Thromboembolism*/prevention & control
Blood Platelets/*metabolism
Platelet Activation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Aged ; Aged, 80 and over ; Coronary Vessels ; Drug Therapy, Combination ; Female ; Humans ; Male ; Risk Factors
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies